Nippon Shinyaku to co-promote Gonal-f in Japan

2 July 2015

Nippon Shinyaku (TYO: 4516) has been granted the right to co-promote Gonal-f (follitropin alfa) in Japan by Merck Serono, a unit of Germany’s Merck KGaA (MRK: DE), and has commenced the promotion and information gathering activities of Gonal-f as of July 1. Financial terms of the accord were not disclosed.

The drug is intended for the treatment of the induction of ovulation in the oligo-anovulatory infertile patients due to functional disorders in hypothalamus and pituitary or polycystic ovary syndrome (OI) and the induction of sperm formation in male hypogonadotropic hypogonadism (MHH).

In Japan, Serono Japan launched Gonal-f for the treatment of MHH in 2006 and Merck Serono Japan (MSJ) launched it for OI in 2009 and has been marketing Gonal-f for both indications since then. Outside Japan, Gonal-f is approved for the treatment of OI and MHH in 103 countries and 92 countries, respectively, and is marketed by Merck Serono worldwide, only in the US and Canada it is sold by EMD Serono.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK